Evidence for a Functional Role of Angiotensin II Type 2 Receptor in the Cardiac Hypertrophic Process in Vivo in the Rat Heart

Circulation

Volumn 108, Issue 19, 2003, Pages 2414-2422

  Lakó Futó, Zoltán ^a   Szokodi, István ^b,c   Sármán, Balázs ^a   Földes, Gábor ^a   Tokola, Heikki ^c   Ilves, Mika ^c   Leskinen, Hanna ^c   Vuolteenaho, Olli ^c   Skoumal, Réka ^a   DeChâtel, Rudolf ^a   Ruskoaho, Heikki ^c   Tóth, Miklós ^a  

^a SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^b UNIVERSITY OF PÉCS   (Hungary)

^c UNIVERSITY OF OULU   (Finland)

Author keywords

Angiotensin; Growth substances; Hypertrophy; Natriuretic peptides; Receptors

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ALPHA ACTIN; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; ENDOTHELIN 1; FIBROBLAST GROWTH FACTOR; MYOSIN HEAVY CHAIN; SOMATOMEDIN C; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; GENE EXPRESSION; HEART LEFT VENTRICLE MASS; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE OVERLOAD; HEART VENTRICLE PRESSURE; HYPERTENSION; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOGENE C FOS; OSMOTIC MINIPUMP; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RECEPTOR BLOCKING;

ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ATRIAL NATRIURETIC FACTOR; BLOOD PRESSURE; CARDIOMYOPATHY, HYPERTROPHIC; FIBROBLAST GROWTH FACTOR 1; GENE EXPRESSION REGULATION; GENES, FOS; HEART RATE; HYPERTENSION; IMIDAZOLES; INFUSION PUMPS, IMPLANTABLE; LOSARTAN; MALE; NATRIURETIC PEPTIDE, BRAIN; PROTO-ONCOGENE PROTEINS C-FOS; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ANGIOTENSIN, TYPE 2; RNA, MESSENGER; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 0242694527     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000093193.63314.D9     Document Type: Article

References (36)

1. de Gasparo M, Catt KJ, Inagami T, et al. International Union of Pharmacology, XXIII. The angiotensin II receptors. Pharmacol Rev. 2000;52:415-472.
2. Dostal DE, Baker KM. The cardiac renin-angiotensin system: conceptual, or a regulator of cardiac function? Circ Rev. 1999;85:643-650.
3. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995-1003.
4. Regitz-Zagrosek V, Friedel N, Heymann A, et al. Regulation, chamber localization, and subtype distribution of angiotensin II receptors in human hearts. Circulation. 1995;91:1461-1471.
5. 2 receptors in the normal and failing human heart. J Pharmacol Exp Ther. 1998:284:323-336.
6. Matsubara H. Pathophysiological role of angiotensin II type 2 receptor in cardiovascular and renal diseases. Circ Res. 1998;83:1182-1191.
7. 1 receptor: gain-of-function study using gene transfer. Proc Natl Acad Sci U S A. 1995:92:10663-10667.
8. 2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest. 1995;95:651-657.
9. Booz GW, Baker KM. Role of type 1 and type 2 angiotensin receptors in angiotensin II-induced cardiomyocyte hypertrophy. Hypertension. 1996:28:635-640.
10. Bartunek J, Weinberg EO, Tajima M, et al. Angiotensin 11 type 2 receptor blockade amplifies the early signals of cardiac growth response to angiotensin II in hypertrophied hearts. Circulation. 1999;99:22-25.
11. Senbonmatsu T, Ichihara S, Price E Jr, et al. Evidence for angiotensin 11 type 2 receptor-mediated cardiac myocyte enlargement during in vivo pressure overload. J Clin Invest. 2000;106:R25-R29.
12. 2-subtype receptors prevents the effect of angiotensin II on the rat vascular structure. J Clin Invest. 1996:98:418-425.
13. 2 angiotensin receptor antagonists in angiotensin II-infused rats. Hypertension. 1998;31:487-492.
14. Sabri A, Samuel JL, Marotte F, et al. Microvasculature in angiotensin II-dependent cardiac hypertrophy in the rat. Hypertension. 1998;32:371-375.
15. 2 receptor ligands CGP 42112 and PD 123319 after blockade of the renin-angiotensin system. Eur J Pharmacol. 1994;259:27-36.
16. Foldes G, Suo M, Szokodi I, et al. Factors derived from adrenals are required for activation of cardiac gene expression in angiotensin II-induced hypertension. Endocrinology. 2001;142:4256-4263.
17. Suo M, Hautala N, Foldes G, et al. Posttranscriptional control of BNP gene expression in angiotensin H-induced hypertension. Hypertension. 2002:39:803-808.
18. Majalahti-Palviainen T, Hirvinen M, Tervonen V, et al. Gene structure of a new cardiac peptide hormone: a model for heart-specific gene expression. Endocrinology. 2000;141:731-740.
19. Molkentin JD, Dorn GW II. Cytoplasmic signaling pathways that regulate cardiac hypertrophy. Annu Rev Physiol. 2001:63:391-426.
20. Oliver PM, Fox JE, Kim R, et al. Hypertension, cardiac hypertrophy, and sudden death in mice lacking natriuretic peptide receptor A. Proc Natl Acad Sci U S A. 1997;94:14730-14735.
21. Knowles JW, Esposito G, Mao L, et al. Pressure-independent enhancement of cardiac hypertrophy in natriuretic peptide receptor A-deficient mice. J Clin Invest. 2001;107:975-984.
22. Opie LH, Sack MN. Enhanced angiotensin II activity in heart failure: reevaluation of the counterregulatory hypothesis of receptor subtypes. Circ Res. 2001;88:654-658.
23. 2, judgment day: which angiotensin receptor is the culprit in cardiac hypertrophy? Circulation. 2001;104:247-248.
24. Ichihara S, Senbonmatsu T, Price E Jr, et al. Angiotensin II type 2 receptor is essential for left ventricular hypertrophy and cardiac fibrosis in chronic angiotensin II-induced hypertension. Circulation. 2001;104:346-351.
25. Akishita M, Iwai M, Wu L, et al. Inhibitory effect of angiotensin II type 2 receptor on coronary arterial remodeling after aortic banding in mice. Circulation. 2000;102:1684-1689.
26. Wu L, Iwai M, Nakagami H, et al. Effect of angiotensin II type 1 receptor blockade on cardiac remodeling in angiotensin II type 2 receptor null mice. Arterioscler Thromb Vasc Biol. 2002;22:49-54.
27. Sechi LA, Griffin CA, Grady EF, et al. Characterization of angiotensin II receptor subtypes in rat heart. Circ Res. 1992;71:1482-1489.
28. Kedzierski RM, Yanagisawa M. Endothelin system: the double-edged sword in health and disease. Annu Rev Pharmacol Toxicol. 2001;41:851-876.
29. Sakai S, Miyauchi T, Yamaguchi I. Long-term endothelin receptor antagonist administration improves alterations in expression of various cardiac genes in failing myocardium of rats with heart failure. Circulation. 2000;101:2849-2853.
30. Matsumoto Y, Aihara H, Yamauchi-Kohno R, et al. Long-term endothelin A receptor blockade inhibits electrical remodeling in cardiomyopathic hamsters. Circulation. 2002;106:613-619.
31. Ren J, Samson WK, Sowers JR. Insulin-like growth factor I as a cardiac hormone: physiological and pathophysiological implications in heart disease. J Mol Cell Cardiol. 1999;31:2049-2061.
32. Neufeld G, Cohen T, Gengrinovitch S, et al. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 1999;13:9-22.
33. Engelmann GL, Dionne CA, Jaye MC. Acidic fibroblast growth factor and heart development: role in myocyte proliferation and capillary angiogenesis. Circ Res. 1993;72:7-19.
34. Tsutamoto T, Hisanaga T, Fukai D, et al. Prognostic value of plasma soluble intercellular adhesion molecule-1 and endothelin-I concentration in patients with chronic congestive heart failure. Am J Cardiol. 1995;76:803-808.
35. Berger R, Huelsman M, Strecker K, et al. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation. 2002;105:2392-2397.
36. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial. The Losartan Heart Failure Survival Study ELITE II. Lancet. 2000;355:1582-1587.